CASE REPORT

Gynecomastia and hypertension in a patient treated with posaconazole

George R. Thompson III1 | Prasanth N. Surampudi2 | Alex Odermatt3

1Department of Internal Medicine, Division of Infectious Diseases, University of California Davis Medical Center, Davis, CA, USA
2Department of Internal Medicine, Division of Endocrinology, University of California Davis Medical Center, Davis, CA, USA
3Swiss Centre for Applied Human Toxicology and Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland

Abstract
Posaconazole therapy may lead to increased serum estradiol levels and development of gynecomastia. Early detection by endocrine hormone measurements may help preventing gynecomastia.

KEYWORDS
11beta-hydroxylase, adverse drug effect, estradiol, gynecomastia, hypertension, hypokalemia, posaconazole

1 INTRODUCTION

We describe a patient with gynecomastia and pseudohyperaldosteronism caused by posaconazole treatment of pulmonary coccidioidomycosis infection. Gynecomastia has not previously been reported in posaconazole therapy. Substitution of posaconazole by voriconazole reversed blood pressure and serum potassium while gynecomastia remained unchanged. Early detection by endocrine measurements may help preventing gynecomastia.

Adverse drug effects account for up to 20% of all cases of gynecomastia. Drugs can disrupt hormonal regulation, thereby affecting ductal growth, alveolar differentiation, and subcutaneous fat deposition, which can contribute to male breast development. In particular, an increase in estradiol and progesterone levels with a concomitant decrease in testosterone can lead to gynecomastia. Drugs enhancing estrogen action promote ductal growth, medications increasing progesterone and prolactin levels can influence alveolar differentiation, and substances reducing androgen levels decrease their inhibitory effects on breast development and result in relatively increased effects of breast-promoting hormones, thereby resulting in male breast development. Other hormones such as growth
hormone (GH), insulin-like growth factor (IGF-1), prolactin, cortisol, and thyroid hormone act as permissive trophic factors and require an imbalance of estrogens and androgens for the development of gynecomastia. The sex steroids estradiol and progesterone require other mediators (eg, GH and IGF-1) to sustain breast development.

The currently available azole antifungal agents used for systemic treatment are not fully selective, and besides blocking fungal ergosterol synthesis by inhibiting lanosterol 14α-demethylase (CYP51), they can cause adverse effects by interfering with human steroidogenic cytochrome P450 (CYP) enzymes. This can lead to adverse drug-drug and drug-hormone interactions. The best-studied example is the imidazole-based antifungal compound ketoconazole, well known to cause gynecomastia, with an incidence of 4%-8% at lower doses (200-400 mg/day) and up to about 21% at higher doses (800-1200 mg/day).2-4 These effects may be most frequent with long-term therapy, subjecting patients to prolonged elevation of the estradiol/testosterone ratio. Ketoconazole has been found to markedly decrease serum testosterone concentrations, with a much smaller effect on estradiol, thereby significantly increasing the estradiol/testosterone ratio.5

Ketoconazole may alter estradiol and testosterone levels through multiple mechanisms. It was found to inhibit the adrenal 11β-hydroxylase (CYP11B1), increasing the 11-deoxycortisol/cortisol ratio by 15- to 80-fold.6 Inhibition of this critical enzymatic step was found in some cases to be associated with gynecomastia, probably due to an enhanced adrenal androgen production because of inhibition of cortisol synthesis. Ketoconazole also inhibits 17α-hydroxylase and 17,20-lyase (both key steps in testosterone synthesis catalyzed by the same enzyme, ie, CYP17A1). As a result, less androgens are produced, and subsequently, also fewer estrogens are formed via aromatase (CYP19A1). Furthermore, ketoconazole can displace estradiol from sex hormone–binding globulin (SHBG),7 potentially resulting in increased estradiol levels. Additionally, ketoconazole can block androgen receptor binding of testosterone and dihydrotestosterone, thereby decreasing androgen signaling and altering the androgen–estrogen balance toward the latter.8 These numerous “off-target” effects retgtulated ketoconazole to the treatment of hypercortisolism and castration-resistant prostate cancer while newer triazole (nonimidazole) antifungals have replaced its use in the treatment of systemic fungal infections.

The newer triazole antifungals (fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole) have not been reported to cause similar endocrinologic manifestations, despite nearly 30 years of clinical experience with these triazoles. A new formulation of posaconazole (delayed-release tablets) has recently become available with resultant increases in serum drug concentrations compared to the previously prescribed oral solution formulation.9 This has been viewed as a favorable clinical development and has been a welcome addition to the antifungal armamentarium, given past studies finding improvements in posaconazole efficacy in the treatment of invasive fungal disease with higher serum drug concentrations.10 These higher levels, although potentially optimizing the efficacy, have recently been observed to be associated with adverse endocrinologic effects, specifically the pseudohyperaldosteronism caused by the inhibition of CYP11B1 and/or 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2).11-13 Although this adverse event has only recently been recognized and less than 20 cases have thus far been reported in detail,14 gynecomastia had previously not been observed in association with posaconazole-induced pseudohyperaldosteronism.

**CASE REPORT**

A 38-year-old African American male with no prior past medical history was diagnosed with pulmonary coccidioidomycosis approximately 11 months prior to referral to the hospital. He initially had symptoms of fever, chills, chest pain, and weight loss, and was found to have a right lower lobe pneumonia and osteomyelitis of the right clavicle consistent with disseminated coccidioidomycosis. Laboratory results returned and were unremarkable with the exception of a positive *Coccidioides* complement fixation titer of 1:32 and a C-reactive protein level of 254 mg/L. He was placed on oral fluconazole 600 mg/day. Over the next 8 weeks, he developed xerosis, cheilitis, and alopecia and refused further fluconazole therapy. He was subsequently transitioned to posaconazole delayed-release tablets 300 mg/d. At return visit 5 months later, he was symptom-free and the patient’s coccidioidal complement fixation titer had decreased to 1:8. However, he had developed new onset of gynecomastia, supported by a mammogram showing benign fibrotic tissue, along with hypertension (blood pressure 155/98, heart rate 51). The mammogram did, however, not reveal any tumor. The normal human chorionic gonadotropin (hCG), follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone, and prolactin levels (Table 1) suggested the absence of prolactinoma or Leydig or Sertoli cell, and adrenal hormone-producing tumors. Furthermore, the patient had no nausea, diarrhea, or vomiting, and he was on no other medication and denied the use of any steroid supplements and estrogen-rich foods.

The development of posaconazole-induced hypertension was further analyzed by laboratory testing (Table 1). As observed in previous cases,11,14,15 posaconazole-induced hypertension was accompanied by hypokalemia and undetectably low aldosterone. In contrast to previous cases, renin was in the normal range, although at the lower end, and neither 11-deoxycortisol level nor the cortisol-to-cortisone ratio was elevated. The other hormones, compared
to reference ranges, assessed were in the normal range, including testosterone; however, estradiol was significantly elevated.

Posaconazole therapy was then discontinued, and the patient was started on voriconazole 200 mg twice daily. The patient returned to clinic 4 months later, and at this time, his endocrinology laboratory values had normalized, with the exception of aldosterone that was now elevated at 31 ng/dL. However, his gynecomastia remained unchanged, although estradiol with 22 pg/mL was almost back to normal range. Nevertheless, testosterone was normal in our patient while estradiol was significantly elevated (Table 1).

Alternatively, posaconazole, like ketoconazole, may result in decreased hepatic degradation of estrogens due to the inhibition of CYP3A4 and CYP3A7. A decreased conversion of estrone to 16a-hydroxyestrone and estradiol to estriol may lead to elevated estrogen levels and a disturbed estrogen to androgen balance. Furthermore, follow-on studies should also include enzymes involved in androgen and estrogen sulfation, and transporters of androgens and estrogens. Additionally, it remains unclear whether posaconazole decreases the binding of sex steroids to SHBG, leading to elevated free concentrations.

In contrast to previously described cases of posaconazole-induced pseudoaldosteronism (PIPH) showing either elevated 11-deoxycortisol and indicating CYP11B1 inhibition, or an increased cortisol to cortisone ratio, a biomarker of decreased 11β-HSD2 activity, this patient presented with 11-deoxycortisol and a cortisol to cortisone ratio in the normal range (Table 1). As previously seen, aldosterone was undetectable but renin was at the lower end of the normal range. The serum posaconazole level was somewhat lower than in most previously reported cases of PIPH showing >3 µg/mL. Thus, the concentration achieved in our patient may not have been high enough to inhibit CYP11B1 and/or 11β-HSD2 sufficiently to cause feedback stimulation, resulting in elevated serum 11-deoxycortisol and/or cortisol to cortisone ratio. It needs to be noted that 24-hour urine, which yields more sensitive information on changes in steroid homeostasis, was not available. The failure to detect aldosterone can be explained by the potent inhibition of aldosterone synthase (CYP11B2), which is more potently inhibited by posaconazole than CYP11B1.12,21 The exact mechanism of hypertension and hypokalemia in this patient remains unclear. Enhanced sensitivity of the mineralocorticoid receptor by enhanced intracellular availability of corticosteroids or post-translational modifications leading to enhanced receptor activation should be considered.

Nevertheless, substitution of posaconazole by voriconazole reversed the adverse effect on blood pressure, serum potassium, and endocrine hormones as seen in previous cases.11,14 The fact that gynecomastia still persisted after discontinuation of posaconazole treatment is not surprising. Even with a return to normal estrogen levels, gynecomastia in males is frequently permanent as the breast tissue undergoes fibrosis, as was seen in our case. This emphasizes the need for detecting disturbances of endocrine hormones as early as possible during posaconazole treatment.
In conclusion, we report the first case of posaconazole-induced gynecomastia and review the known adrenal enzymatic pathways responsible for the development of drug-induced gynecomastia. Future work further delineating the exact pathophysiologic mechanism(s) behind posaconazole-induced gynecomastia should be undertaken to more fully understand what might be an underreported phenomenon.

ACKNOWLEDGMENTS
Published with written consent of the patient.

CONFLICT OF INTEREST
None declared.

AUTHOR CONTRIBUTIONS
GRT and PNS: assessed patient data. GRT, PNS, and AO: designed the concept of the manuscript, performed the literature search, defined the intellectual content, and wrote the manuscript.

ETHICAL APPROVAL
This study was approved by the institutional review board of the University of California, Davis School of Medicine, Davis, USA. The patient gave consent to the study but was lost for follow-up.

ORCID
Alex Odermatt https://orcid.org/0000-0002-6820-2712

REFERENCES
1. Bowman JD, Kim H, Bustamante JJ. Drug-induced gynecomastia. Pharmacotherapy. 2012;32:1123-1140.
2. DeFelice R, Johnson DG, Galgiani JN. Gynecomastia with ketoconazole. Antimicrob Agents Chemother. 1981;19:1073-1074.
3. Pont A, Williams PL, Loose DS, et al. Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med. 1982;97:370-372.
4. Pont A, Graybill JR, Craven PC, et al. High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med. 1984;144:2150-2153.
5. Pont A, Goldman ES, Sugar AM, Siiteri PK, Stevens DA. Ketoconazole-induced increase in estradiol-testosterone ratio. Probable explanation for gynecomastia. Arch Intern Med. 1985;145:1429-1431.
6. Engelhardt D, Dorr G, Jaspers C, Knorr D. Ketoconazole blocks cortisol secretion in man by inhibition of adrenal 11 beta-hydroxylase. Klin Wochenschr. 1985;63:607-612.
7. Grosso DS, Boyden TW, Pamenter RW, Johnson DG, Stevens DA, Galgiani JN. Ketoconazole inhibition of testicular secretion of testosterone and displacement of steroid hormones from serum transport proteins. Antimicrob Agents Chemother. 1983;23:207-212.
8. Thompson DF, Carter JR. Drug-induced gynecomastia. Pharmacotherapy. 1993;13:37-45.
9. Jung DS, Tverdek FP, Kontoyiannis DP. Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity. Antimicrob Agents Chemother. 2014;58:6993-6995.
10. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44:2-12.
11. Thompson GR 3rd, Beck KR, Patt M, Kratschmar DV, Odermatt A. Posaconazole-Induced Hypertension Due to Inhibition of 11beta-Hydroxylase and 11beta-Hydroxysteroid Dehydrogenase 2. J Endocr Soc. 2019;3:1361-1366.
12. Beck KR, Telisman L, van Koppen CJ, Thompson GR 3rd, Odermatt A. Molecular mechanisms of posaconazole- and itraconazole-induced pseudohyperaldosteronism and assessment of other systemically used azole antifungals. J Steroid Biochem Mol Biol. 2020;199:105605.
13. Nguyen MH, Davis MR, Wittenberg R, et al. Posaconazole Serum Drug Levels Associated With Pseudohyperaldosteronism. Clin Infect Dis. 2020;70:2593-2598.
14. Beck KR, Thompson GR 3rd, Odermatt A. Drug-induced endocrine blood pressure elevation. Pharmacol Res. 2020;154:104311.
15. Boughton C, Taylor D, GhaatooRE, Taylor N, Whitelaw BC. Mineralocorticoid hypertension and hypokalemia induced by posaconazole. Endocrinol Diabetes Metab Case Rep. 2018;2018:17-0157.
16. Kratz A, Ferraro M, Sluss PM, Lewandrowski KB. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Laboratory reference values. N Engl J Med. 2004;351:1548-1563.
17. Nakamoto JM, Mason PW. Endocrinology: Test Selection and Interpretation. The Quest Diagnostics Manual. 5th Edition. 2012. Quest Diagnostics.
18. Thompson GR 3rd, Chang D, Wittenberg RR, McHardy I, Semrad A. In Vivo 11beta-Hydroxysteroid Dehydrogenase Inhibition in Posaconazole-Induced Hypertension and Hypokalemia. Antimicrob Agents Chemother. 2017;61:e00760-17.
19. Blackett MP, Freeman MD. Androstenedione aromatization as a cause of gynecomastia in 11beta-hydroxylase and 21-hydroxylase deficiencies. Endocr Pract. 1996;2:90-93.
20. Hochberg Z, Even L, Zadik Z. Mineralocorticoids in the mechanism of gynecomastia in 11beta-hydroxylase deficiency. J Pediatr. 1991;118:258-260.
21. Yates CM, Garvey EP, Shaver SR, Schotzinger RJ, Hoekstra WJ. Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors. Bioorg Med Chem Lett. 2017;27:3243-3248.
22. Barton K, Davis TK, Marshall B, Elward A, White NH. Posaconazole-induced hypertension and hypokalemia due to inhibition of the 11beta-hydroxylase enzyme. Clin Kidney J. 2018;11:691-693.

How to cite this article: Thompson GR III, Surampudi PN, Odermatt A. Gynecomastia and hypertension in a patient treated with posaconazole. Clin. Case Rep. 2020;8:3157–3160. https://doi.org/10.1002/ccr3.3376